CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Crizotinibdrug
Likely dose
Crizotinib 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02223819
NCT02223819Phase 2Completed
CompareCT.gov

Phase II Trial of Adjuvant Crizotinib in High-Risk Uveal Melanoma Following Definitive Therapy

Columbia University·interventional·Posted Aug 22, 2014·Updated Dec 6, 2023

In Brief

A Phase 2 clinical trial evaluating Crizotinib for Uveal Melanoma. Completed, enrolled 34 participants across 4 sites.

Detailed Summary

The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in this patient population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUveal Melanoma
CountriesUnited States
CollaboratorsPfizer

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedAug 22, 2014
Enrollment StartMar 1, 2015
Primary CompletionJul 3, 2019
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 11.9 years ago

Interventions

Crizotinibdrug

An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK. Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration.